Immunosuppressive mechanisms of malignant gliomas: Parallels at non-CNS sites

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Perng, Powell ^a   Lim, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2, 3 DIOXYGENASE; INTERLEUKIN 10; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; BONE MARROW CELL; BRAIN PERICYTE; BRAIN TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM FUNCTION; GLIOBLASTOMA; HOMEOSTASIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOMA; MICROGLIA; REGULATORY T LYMPHOCYTE; REVIEW; TRYPTOPHAN METABOLISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84935143364     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00153     Document Type: Review

References (359)

1. Lampson LA, Brain tumor immunotherapy: seeing the brain in the body. Drug Discov Today, 2013.18(7-8): p. 399-406.
2. Forrester JV, Xu H, Lambe T, and Cornall R, Immune privilege or privileged immunity? Mucosal Immunol, 2008.1(5): p. 372-81.
3. Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, et al., CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol, 2007. 178(4): p. 2278-86.
4. Klein RS, Izikson L, Means T, Gibson HD, Lin E, Sobel RA, et al., IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol, 2004.172(1): p. 550-9.
5. Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand- Lions M, et al., Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity, 2005. 22(2): p. 175-84.
6. Konnecke H and Bechmann I, The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol, 2013. 2013: p. 914104.
7. Bechmann I, Galea I, and Perry VH, What is the blood-brain barrier (not)? Trends in Immunology, 2007. 28(1): p. 5-11.
8. Reid DM, Perry VH, Andersson PB, and Gordon S, Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. Neuroscience, 1993. 56(3): p. 529-33.
9. Ohtsuki S and Terasaki T, Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res, 2007. 24(9): p. 1745-58.
10. Tamai I and Tsuji A, Transporter-mediated permeation of drugs across the bloodbrain barrier. J Pharm Sci, 2000. 89(11): p. 1371-88.
11. Roopenian DC and Akilesh S, FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol, 2007. 7(9): p. 715-25.
12. Ward ES and Ober RJ, Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol, 2009.103: p. 77-115.
13. Lampson LA, Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. mAbs, 2011. 3(2): p. 153-60.
14. Cserr HF and Knopf PM, Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today, 1992.13(12): p. 507-12.
15. Weller RO, Kida S, and Zhang ET, Pathways of fluid drainage from the brainmorphological aspects and immunological significance in rat and man. Brain Pathol, 1992. 2(4): p. 277-84.
16. Cserr HF, Harling-Berg CJ, and Knopf PM, Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol, 1992. 2(4): p. 269-76.
17. Laman JD and Weller RO, Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J Neuroimmune Pharmacol, 2013. 8(4): p. 840-56.
18. Harris MG, Hulseberg P, Ling C, Karman J, Clarkson BD, Harding JS, et al., Immune privilege of the CNS is not the consequence of limited antigen sampling. Scientific Reports, 2014. 4.
19. Engelhardt B and Ransohoff RM, Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends in Immunology, 2012. 33(12): p. 579-89.
20. Owens T, Bechmann I, and Engelhardt B, Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol, 2008. 67(12): p. 1113-21.
21. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, and Naftolin F, FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia, 1999. 27(1): p. 62-74.
22. Pender MP, Nguyen KB, McCombe PA, and Kerr JF, Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci, 1991.104(1): p. 81-7.
23. Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Lee HK, et al., Immunohistochemical analysis of Fas ligand expression in normal human tissues. Apmis, 1999.107(11): p. 1013-9.
24. Xerri L, Devilard E, Hassoun J, Mawas C, and Birg F, Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol, 1997. 50(2): p. 87-91.
25. French LE and Tschopp J, Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring Inst Mitt, 1996(97): p. 156-60.
26. Rossi M and Young JW, Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol, 2005.175(3): p. 1373-81.
27. Neefjes J, Jongsma ML, Paul P, and Bakke O, Towards a systems understanding ofMHC class I and MHC class II antigen presentation. Nat Rev Immunol, 2011.11(12): p. 823-36.
28. Joffre OP, Segura E, Savina A, and Amigorena S, Cross-presentation by dendritic cells. Nat Rev Immunol, 2012.12(8): p. 557-69.
29. McDonnell AM, Robinson BWS, and Currie AJ, Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins? Clinical and Developmental Immunology, 2010. 2010(3): p. 1-9.
30. Xu LW, Chow KK, Lim M, and Li G, Current vaccine trials in glioblastoma: a review. Journal of Immunology Research, 2014. 2014: p. 796856.
31. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010. 363(5): p. 411-22.
32. Beauvillain C, Donnou S, Jarry U, Scotet M, Gascan H, Delneste Y, et al., Neonatal and adult microglia cross-present exogenous antigens. Glia, 2008. 56(1): p. 69-77.
33. Flugel A, Labeur MS, Grasbon-Frodl EM, Kreutzberg GW, and Graeber MB, Microglia only weakly present glioma antigen to cytotoxic T cells. IntJ Dev Neurosci, 1999. 17(5-6): p. 547-56.
34. Jarry U, Jeannin P, Pineau L, Donnou S, Delneste Y, and Couez D, Efficiently stimulated adult microglia cross-prime naive CD8 +T cells injected in the brain. European Journal of Immunology, 2013. 43(5): p. 1173-1184.
35. DAgostino PM, Gottfried-Blackmore A, Anandasabapathy N, and Bulloch K, Brain dendritic cells: biology and pathology. Acta Neuropathologica, 2012.124(5): p. 599-614.
36. Badie B, Bartley B, and Schartner J, Differential expression ofMHC class II and B7 costimulatory molecules by microglia in rodent gliomas. Journal of Neuroimmunology, 2002.133(1-2): p. 39-45.
37. Tran CT, Wolz P, Egensperger R, Kosel S, Imai Y, Bise K, et al., Differential expression ofMHC class II molecules by microglia and neoplastic astroglia: relevance for the escape of astrocytoma cells from immune surveillance. Neuropathol Appl Neurobiol, 1998. 24(4): p. 293-301.
38. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, et al., Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. IntJ Cancer, 2000. 89(3): p. 251-8.
39. Prados MD and Levin V, Biology and treatment of malignant glioma. Semin Oncol, 2000. 27(3Suppl6):p. 1-10.
40. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, and Badie B, Impaired capacity for upregulation ofMHC class II in tumor-associated microglia. Glia, 2005. 51(4): p. 279-85.
41. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, and Anderson DE, Astrocytic regulation of human monocytic/microglial activation. J Immunol, 2008.181(8): p. 5425-32.
42. Moore KW, de Waal Malefyt R, Coffman RL, and O'Garra A, Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology, 2001.19: p. 683-765.
43. Randolph GJ, Jakubzick C, and Qu C, Antigen presentation by monocytes and monocyte-derived cells. Current Opinion in Immunology, 2008. 20(1): p. 52-60.
44. Parney IF, Waldron JS, and Parsa AT, Flow cytometry and in vitro analysis of human glioma-associated macrophages. Journal of Neurosurgery, 2009.110(3): p. 572-582.
45. Mack CL, Vanderlugt-Castaneda CL, Neville KL, and Miller SD, Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler's virus model of multiple sclerosis. Journal of Neuroimmunology, 2003.144(1-2): p. 68-79.
46. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, and Heimberger AB, The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology, 2006. 8(3): p. 261-79.
47. Wei J, Gabrusiewicz K, and Heimberger A, The Controversial Role of Microglia in Malignant Gliomas. Clinical and Developmental Immunology, 2013. 2013(4): p. 1-12.
48. Rodriguez-Pinto D, B cells as antigen presenting cells. CELLULAR IMMUNOLOGY, 2005. 238(2): p. 67-75.
49. Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, et al., B cells are critical to T-cell-mediated antitumor immunity induced by a combined immunestimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia, 2011. 13(10): p. 947-60.
50. Ribeiro AL and Okamoto OK, Combined effects of pericytes in the tumor microenvironment. Stem Cells Int, 2015. 2015: p. 868475.
51. Pieper C, Marek JJ, Unterberg M, Schwerdtle T, and Galla HJ, Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro. Brain Res, 2014 1550: p. 1-8.
52. Bose A, BarikS, Banerjee S, Ghosh T, MallickA, Bhattacharyya Majumdar S, etal., Tumor-derived vascular pericytes anergize Th cells. J Immunol, 2013.191(2): p. 971-81.
53. Thompson ED, Enriquez HL, Fu YX, and Engelhard VH, Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. Journal of Experimental Medicine, 2010. 207(8): p. 1791-1804 54. Kundig TM, Shahinian A, Kawai K, Mittrucker HW, Sebzda E, Bachmann MF, et al., Duration of TCR stimulation determines costimulatory requirement of Tcells. Immunity, 1996. 5(1): p. 41-52.
54. Kundig TM, Shahinian A, Kawai K, Mittrucker HW, Sebzda E, Bachmann MF, et al., Duration of TCR stimulation determines costimulatory requirement of Tcells. Immunity, 1996. 5(1): p. 41-52
55. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, and Walker PR, Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells. The Journal of Immunology, 2007.179(2): p. 845-853.
56. Walter L and Albert ML, Cutting edge: cross-presented intracranial antigen primes CD8+ Tcells. J Immunol, 2007.178(10): p. 6038-42.
57. Okamoto Y, Yamashita J, Hasegawa M, Fujisawa H, Yamashima T, Hashimoto T, et al., Cervical lymph nodes play the role of regional lymph nodes in brain tumour immunity in rats. Neuropathol Appl Neurobiol, 1999. 25(2): p. 113-22.
58. El-Asady R, Yuan R, Liu K, Wang D, Gress RE, Lucas PJ, et al., TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium duringgraft-versus-host disease. J Exp Med, 2005. 201(10): p. 1647-57.
59. Fischer HG and Reichmann G, Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol, 2001.166(4): p. 2717-26.
60. Melief CJ, Cancer immunotherapy by dendritic cells. Immunity, 2008. 29(3): p. 372-83.
61. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al., Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic Tcell immunity. Science, 2008. 322(5904): p. 1097-100.
62. Zinkernagel RM, On cross-priming ofMHC class I-specific CTL: rule or exception? European Journal of Immunology, 2002. 32(9): p. 2385-92.
63. McDonnell AM, Prosser AC, van Bruggen I, Robinson BW, and Currie AJ, CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. European Journal of Immunology, 2010. 40(6): p. 1617-27.
64. van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, et al., Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol, 2004.173(11): p. 6753-9.
65. Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, et al., Enhanced CD8 Tcell cross-presentation by macrophages with targeted disruption ofSTAT3. Immunol Lett, 2010.131(2): p. 126-30.
66. Lin ML, Zhan Y, Villadangos JA, and Lew AM, The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol, 2008. 86(4): p. 353-62.
67. Pozzi LA, Maciaszek JW, and Rock KL, Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol, 2005.175(4): p. 2071-81.
68. Bosma BM, Metselaar HJ, Mancham S, Boor PP, Kusters JG, Kazemier G, et al., Characterization of human liver dendritic cells in liver grafts and perfusates. Liver Transpl, 2006.12(3): p. 384-93.
69. John R and Nelson PJ, Dendritic cells in the kidney. J Am Soc Nephrol, 2007.18(10): p. 2628-35.
70. Segura E, Durand M, and Amigorena S, Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med, 2013. 210(5): p. 1035-47.
71. Ballesteros-Tato A, Leon B, Lund FE, and Randall TD, Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) Tcell responses to influenza. Nature Immunology, 2010.11(3): p. 216-24.
72. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, et al., Crosspresentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nature Immunology, 2009.10(5): p. 488-95.
73. del Rio ML, Rodriguez-Barbosa JI, Kremmer E, and Forster R, CD103-and CD103+ bronchial lymph node dendritic cells are specialized in presenting and crosspresenting innocuous antigen to CD4+ and CD8+ Tcells. J Immunol, 2007.178(11): p. 6861-6.
74. Akbari O, DeKruyff RH, and Umetsu DT, Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nature Immunology, 2001. 2(8): p. 725-31.
75. Belz GT, Smith CM, Kleinert L, Reading P, Brooks A, Shortman K, et al., Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class Irestricted antigen presentation after lung infection with virus. Proc Natl Acad Sci U S A, 2004.101(23): p. 8670-5.
76. Chung Y, Chang JH, Kim BS, Lee JM, Kim HY, and Kang CY, Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens. European Journal of Immunology, 2007. 37(6): p. 1453-62.
77. Wojas K, Tabarkiewicz J, Jankiewicz M, and Rolinski J, Dendritic cells in peripheral blood of patients with breast and lung cancer--a pilot study. Folia Histochem Cytobiol, 2004. 42(1): p. 45-8.
78. Ahmadi T, Flies A, Efebera Y, and Sherr DH, CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology, 2008.124(1): p. 129-40.
79. Ren H, Zhao S, Li W, Dong H, Zhou M, Cao M, et al., Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles). J Immunother, 2014. 37(8): p. 383-93.
80. Alvarez D, Vollmann EH, and von Andrian UH, Mechanisms and consequences of dendritic cell migration. Immunity, 2008. 29(3): p. 325-42.
81. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, et al., Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity, 2006. 25(1): p. 153-62.
82. GeurtsvanKessel CH, Willart MA, van Rijt LS, Muskens F, Kool M, Baas C, et al., Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J Exp Med, 2008. 205(7): p. 1621-34.
83. Steinman RM, Hawiger D, and Nussenzweig MC, Tolerogenic dendritic cells. Annual Review of Immunology, 2003. 21: p. 685-711.
84. Villadangos JA and Schnorrer P, Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol, 2007. 7(7): p. 543-55.
85. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al., Immunobiology of dendritic cells. Annual Review of Immunology, 2000.18: p. 767-811.
86. Galea I, Bechmann I, and Perry VH, What is immune privilege (not)? Trends in Immunology, 2007. 28(1): p. 12-8.
87. Karman J, Ling C, Sandor M, and Fabry Z, Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol, 2004.173(4): p. 2353-61.
88. Hatterer E, Davoust N, Didier-Bazes M, Vuaillat C, Malcus C, Belin MF, et al., How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood, 2006.107(2): p. 806-12.
89. Weller RO, Djuanda E, Yow HY, and Carare RO, Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathologica, 2009.117(1): p. 1-14.
90. Gerner MY, Casey KA, and Mescher MF, Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol, 2008.181(1): p. 155-64.
91. Gerner MY and Mescher MF, Antigen processing and MHC-IIpresentation by dermal and tumor-infiltrating dendritic cells. J Immunol, 2009.182(5): p. 2726-37.
92. Ishida T, Oyama T, Carbone DP, and Gabrilovich DI, Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol, 1998.161(9): p. 4842-51.
93. Preynat-Seauve O, Contassot E, Schuler P, French LE, and Huard B, Melanomainfiltrating dendritic cells induce protective antitumor responses mediated by T cells. Melanoma Res, 2007.17(3): p. 169-76.
94. Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, et al., Tumormediated liverXreceptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nature Medicine, 2010.16(1): p. 98-105.
95. Dennis KL, Blatner NR, Gounari F, and Khazaie K, Current status of interleukin-10 and regulatory T-cellsin cancer. Current Opinion in Oncology, 2013. 25(6): p. 637-45.
96. McDonnell AM, Currie AJ, Brown M, Kania K, Wylie B, Cleaver A, et al., Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. OncoImmunology, 2014.1(6): p. 840-846.
97. Mapara MY and Sykes M, Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol, 2004. 22(6): p. 1136-51.
98. Marincola FM, Jaffee EM, Hicklin DJ, and Ferrone S, Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol, 2000. 74: p. 181-273.
99. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, and O'Garra A, IL-10 inhibits cytokine production by activated macrophages. J Immunol, 1991.147(11): p. 3815-22.
100. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, et al., SOCS3 negatively regulates IL-6 signaling in vivo. Nature Immunology, 2003.4(6): p. 540-5.
101. Murray PJ, The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci USA, 2005.102(24): p. 8686-91.
102. Lang R, Patel D, Morris JJ, Rutschman RL, and Murray PJ, Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol, 2002.169(5): p. 2253-63.
103. Ishido S, Goto E, Matsuki Y, and Ohmura-Hoshino M, E3 ubiquitin ligasesforMHC molecules. Current Opinion in Immunology, 2009. 21(1): p. 78-83.
104. Thibodeau J, Bourgeois-DaigneaultMC, Huppe G, TremblayJ, AumontA, Houde M, et al., Interleukin-10-induced MARCH1 mediates intracellular sequestration ofMHC class II in monocytes. European Journal of Immunology, 2008. 38(5): p. 1225-30.
105. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, et al., Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nature Immunology, 2009.10(11): p. 1178-84.
106. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, et al., Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. Nature Immunology, 2007. 8(9): p. 931-41.
107. Mocellin S, Marincola FM, and Young HA, Interleukin-10 and the immune response against cancer: a counterpoint. Journal of Leukocyte Biology, 2005. 78(5): p. 1043-51.
108. Vieira P, de Waal-Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, et al., Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA, 1991. 88(4): p. 1172-6.
109. Cai G, Kastelein RA, and Hunter CA, IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. European Journal of Immunology, 1999. 29(9): p. 2658-65.
110. MacNeil IA, Suda T, Moore KW, Mosmann TR, and Zlotnik A, IL-10, a novel growth cofactor for mature and immature Tcells. J Immunol, 1990.145(12): p.4167-73.
111. Suda T, O'Garra A, MacNeil I, Fischer M, Bond MW, and Zlotnik A, Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. CELLULAR IMMUNOLOGY, 1990.129(1): p. 228-40.
112. OGarra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rugo H, et al., Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol, 1990. 2(9): p. 821-32.
113. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, et al., Interleukin 10, a novel B cell stimulatory factor: unresponsiveness ofX chromosome-linked immunodeficiency B cells. J Exp Med, 1990.172(6): p. 1625-31.
114. Chen WF and Zlotnik A, IL-10: a novel cytotoxic T cell differentiation factor. J Immunol, 1991.147(2): p. 528-34.
115. Huang S, Ullrich SE, and Bar-Eli M, Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res, 1999.19(7): p. 697-703.
116. Kundu N, Beaty TL, Jackson MJ, and Fulton AM, Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst, 1996. 88(8): p. 536-41.
117. Huettner C, Paulus W, and Roggendorf W, Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol, 1995.146(2): p. 317-22.
118. Wagner S, Czub S, Greif M, Vince GH, Suss N, Kerkau S, et al., Microglial/macrophage expression of interleukin 10 in human glioblastomas. IntJ Cancer, 1999. 82(1): p. 12-6.
119. Hishii M, Nitta T, Ishida H, Ebato M, Kurosu A, Yagita H, et al., Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery, 1995. 37(6): p. 1160-6; discussion 1166-7.
120. Van Meir EG, Cytokines and tumors of the central nervous system. Glia, 1995.15(3): p. 264-88.
121. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, and Parsa AT, Gliomas Promote Immunosuppression through Induction ofB7-H1 Expression in Tumor-Associated Macrophages. Clinical Cancer Research, 2013.19(12): p. 3165-3175.
122. Wilmotte R, Burkhardt K, Kindler V, Belkouch MC, Dussex G, Tribolet N, et al., B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport, 2005.16(10): p. 1081-5.
123. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, et al., Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 2003. 63(21): p. 7462-7.
124. Huettner C, Czub S, Kerkau S, Roggendorf W, and Tonn JC, Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res, 1997.17(5A): p. 3217-24.
125. Wagner S, Stegen C, Bouterfa H, Huettner C, Kerkau S, Roggendorf W, et al., Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10. J Neurooncol, 1998. 40(2): p. 113-22.
126. Book AA, Fielding KE, Kundu N, Wilson MA, Fulton AM, and Laterra J, IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2. Journal of Neuroimmunology, 1998. 92(1-2): p. 50-9.
127. De Vleeschouwer S, Spencer Lopes I, Ceuppens JL, and Van Gool SW, Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J Neurooncol, 2007. 84(2): p. 131-40.
128. MacKenzie CR, Gonzalez RG, Kniep E, Roch S, and Daubener W, Cytokine mediated regulation of interferon-gamma-induced IDO activation. Adv Exp Med Biol, 1999. 467: p. 533-9.
129. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, et al., Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA, 1992. 89(16): p. 7708-12.
130. Venetsanakos E, Beckman I, Bradley J, and Skinner JM, High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. British Journal of Cancer, 1997. 75(12): p. 1826-30.
131. Knoefel B, Nuske K, Steiner T, Junker K, Kosmehl H, Rebstock K, et al., Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate Tlymphocyte blast transformation. J Interferon Cytokine Res, 1997.17(2): p. 95-102.
132. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al., Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Research, 1995. 55(17): p. 3847-53.
133. Kim J, Modlin RL, Moy RL, DubinettSM, McHugh T, Nickoloff BJ, etal., IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local Tcell immune response. J Immunol, 1995.155(4): p. 2240-7.
134. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, et al., Interleukin 10 production by human melanoma. Clin Cancer Res, 1996. 2(8): p. 1383-90.
135. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, etal., Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. IntJ Cancer, 1997. 71(4): p. 630-7.
136. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, et al., Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol, 1994. 145(1): p. 18-25.
137. Bolpetti A, Silva JS, Villa LL, and Lepique AP, Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunology, 2010.11: p. 27.
138. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, et al., Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med, 1996.184(2): p. 579-84.
139. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, and Sorg C, Macrophages and angiogenesis. Journal of Leukocyte Biology, 1994. 55(3): p. 410-22.
140. Oft M, IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res, 2014. 2(3): p. 194-9.
141. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, et al., Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest, 1996. 98(4): p. 1010-20.
142. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, et al., Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med, 2009. 361(21): p. 2033-45.
143. Begue B, Verdier J, Rieux-Laucat F, GouletO, Morali A, Canioni D, etal., Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol, 2011.106(8): p. 1544-55.
144. Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, et al., A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood, 2013.122(23): p. 3713-22.
145. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al., IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell, 2011. 20(6): p. 781-96.
146. Akhurst RJ and Hata A, Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov, 2012.11(10): p. 790-811.
147. Massagué J, TGFβ in Cancer. Cell, 2008.134(2): p. 215-230.
148. Bierie B and Moses HL, Tumour microenvironment: TGFβ: the molecularJekyll and Hyde of cancer. Nature Reviews Cancer, 2006. 6(7): p. 506-520.
149. Levy L and Hill C, Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine & Growth Factor Reviews, 2006.17(1-2): p. 41-58.
150. Brooks WH, Netsky MG, Normansell DE, and Horwitz DA, Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med, 1972.136(6): p. 1631-47.
151. Kaminska B, TGF Beta Signaling and Its Role in Glioma Pathogenesis. Glioma Signaling, ed. J. Baranska2012: Springer Science. 1-233.
152. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, et al., Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest, 2005. 85(3): p. 328-41.
153. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, et al., RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Research, 2004. 64(20): p. 7596-603.
154. Thomas DA and Massagué J, TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell, 2005. 8(5): p. 369-380.
155. Pen A, Moreno MJ, Durocher Y, Deb-Rinker P, and Stanimirovic DB, Glioblastomasecretedfactors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene, 2008. 27(54): p. 6834-44.
156. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, et al., TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell, 2010.18(6): p. 655-68.
157. Jennings MT and Pietenpol JA, The role of transforming growth factor beta in glioma progression. J Neurooncol, 1998. 36(2): p. 123-40.
158. Wick W, Platten M, and Weller M, Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol, 2001. 53(2): p. 177-85.
159. Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, et al., Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro- Oncology, 2007. 9(3): p. 259-70.
160. Zhang M, Kleber S, Rohrich M, Timke C, Han N, TuettenbergJ, etal., Blockade ofTGFSignaling by the TGF R-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma. Cancer Research, 2011. 71(23): p. 7155-7167.
161. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer- Blass B, et al., Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev, 2006.17(1-2): p. 129-39.
162. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, et al., Inhibition ofTGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/IIstudies. Oligonucleotides, 2007.17(2): p. 201-12.
163. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al., Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology, 2011.13(1): p. 132-42.
164. Wick W and Weller M, Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). Neuro-Oncology, 2011.13(5): p. 559-60; author reply 561-2.
165. Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, et al., Firstin- Human Dose Study of the Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clin Cancer Res, 2015. 21(3): p. 553-60.
166. Maier A, Peille AL, Vuaroqueaux V, and Lahn M, Anti-tumor activity of the TGF-beta receptor kinase inhibitorgalunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol (Dordr), 2015.
167. Kovacs RJ, Maldonado G, Azaro A, Fernandez MS, Romero FL, Sepulveda-Sanchez JM, et al., Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol, 2014.
168. Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, etal., Defining a therapeutic window for the novel TGF-beta inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol, 2014. 77(5): p. 796-807.
169. Derynck R, Akhurst RJ, and Balmain A, TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 2001. 29(2): p. 117-29.
170. Coffey RJ, Jr., Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE, and Moses HL, Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol, 1988. 8(8): p. 3088-93.
171. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, and Massague J, Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell, 1990. 62(1): p. 175-85.
172. Moses HL, Yang EY, and Pietenpol JA, TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell, 1990. 63(2): p. 245-7.
173. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al., Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science, 1995. 268(5215): p. 1336-8.
174. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, et al., A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Research, 1995. 55(23): p. 5545-7.
175. Lu SL, Zhang WC, Akiyama Y, Nomizu T, and Yuasa Y, Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Research, 1996. 56(20): p. 4595-8.
176. Lu SL, Akiyama Y, Nagasaki H, Nomizu T, Ikeda E, Baba S, et al., Loss or somatic mutations ofhMSH2 occur in hereditary nonpolyposis colorectal cancers with hMSH2 germline mutations. Jpn J Cancer Res, 1996. 87(3): p. 279-87.
177. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, and Doetschman T, Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Research, 1999. 59(14): p. 3379-86.
178. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al., Microsatellite instability and the role ofhMSH2 in sporadic colorectalcancer. Oncogene, 1996.12(12): p. 2641-9.
179. Carlin JM, Borden EC, Sondel PM, and Byrne GI, Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol, 1987.139(7): p. 2414-8.
180. Carlin JM, Borden EC, Sondel PM, and Byrne GI, Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. Journal of Leukocyte Biology, 1989. 45(1): p. 29-34.
181. Belladonna ML, Puccetti P, Orabona C, Fallarino F, Vacca C, Volpi C, et al., Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation, 2007. 84(1 Suppl): p. S17-20.
182. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, and Young HA, Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol, 2000.164(7): p. 3596-9.
183. Castro MG, Baker GJ, and Lowenstein PR, Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier! Clinical Cancer Research, 2014. 20(20): p. 5147-5149.
184. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al., IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res, 2012.18(22): p. 6110-21.
185. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine, 2003. 9(10): p. 1269-74.
186. Lesniak MS, Targeting Tregs in malignant brain cancer: overcoming IDO. 2013: p. 1-17.
187. Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, and Kinouchi H, Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery, 2013. 72(6): p. 1031-8; discussion 1038-9.
188. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, and Heimberger AB, Preferential migration of regulatory Tcells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunology, Immunotherapy, 2007. 57(1): p. 123-131.
189. Crane CA, Ahn BJ, Han SJ, and Parsa AT, Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-Oncology, 2012.14(5): p. 584-595.
190. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, et al., IDO activates regulatory T cells and blocks their conversion into Th1 7-like T cells. J Immunol, 2009. 83(4): p. 2475-83.
191. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al., Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest, 2007.117(9): p. 2570-82.
192. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest, 2004 114(2): p. 280-90.
193. Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, et al., Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res, 2015. 3(2): p. 161-72.
194. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, et al., Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PDL1 in Mice with Brain Tumors. Clinical Cancer Research, 2014. 20(20): p. 5290-5301.
195. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, and Prendergast GC, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine, 2005. 11(3): p. 312-319.
196. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al., Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research, 2007. 67(2): p. 792-801.
197. Huehn J, Polansky JK, and Hamann A, Epigenetic control ofFOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol, 2009. 9(2): p. 83-9.
198. Zou W, Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol, 2006. 6(4): p. 295-307.
199. Fujimoto S, Greene M, and Sehon AH, Immunosuppressor T cells in tumor bearing host. Immunol Commun, 1975. 4(3): p. 201-17.
200. Bursuker I and North RJ, Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med, 1984.159(5): p. 1312-21.
201. deLeeuw RJ, Kost SE, Kakal JA, and Nelson BH, The Prognostic Value ofFoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature. Clinical Cancer Research, 2012.18(11): p. 3022-3029.
202. Adeegbe DO and Nishikawa H, Natural and induced T regulatory cells in cancer. Front Immunol, 2013. 4: p. 190.
203. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, and Rudensky AY, Genome-wide analysis ofFoxp3 target genes in developing and mature regulatory T cells. Nature, 2007. 445(7130): p. 936-40.
204. Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst CN, et al., Neuropilin 1 is expressed on thymus-derived natural regulatory Tcells, but not mucosa-generated inducedFoxp3+ Treg cells. J Exp Med, 2012. 209(10): p. 1723-42, S1.
205. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, et al., Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med, 2012. 209(10): p. 1713-22, S1-19.
206. Gottschalk RA, Corse E, and Allison JP, Expression of Helios in peripherally induced Foxp3+ regulatory Tcells. J Immunol, 2012.188(3): p. 976-80.
207. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al., Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ Tregulatory cells. J Immunol, 2010. 184(7): p. 3433-41.
208. Colombo MP and Piconese S, Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer, 2007. 7(11): p. 880-7.
209. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al., Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol, 1998.10(12): p. 1969-80.
210. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al., Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic Tlymphocyte-associated antigen 4. J Exp Med, 2000.192(2): p. 303-10.
211. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, and Sakaguchi S, Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunology, 2002. 3(2): p. 135-42.
212. Piconese S, Valzasina B, and Colombo MP, OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med, 2008. 205(4): p. 825-39.
213. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, and Colombo MP, Triggering ofOX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR Blood, 2005.105(7): p. 2845-51.
214. Whiteside TL, What are regulatory T cells (Treg) regulating in cancer and why? Seminars in Cancer Biology, 2012. 22(4): p. 327-334.
215. Wang L, Zhang B, Xu X, Zhang S, Yan X, Kong F, et al., Clinical significance ofFOXP3 expression in human gliomas. Clin Transl Oncol, 2014.16(1): p. 36-43.
216. Yue Q, Zhang X, Ye HX, WangY, Du ZG, Yao Y, etal., The prognostic value ofFoxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol, 2014. 116(2): p. 251-9.
217. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, et al., Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res, 2011.17(13): p. 4296-308.
218. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, et al., Incidence and prognostic impact ofFoxP3+ regulatory T cells in human gliomas. Clin Cancer Res, 2008.14(16): p. 5166-72.
219. Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, OlekS, etal., Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro- Oncology, 2015.
220. Wainwright DA, Sengupta S, Han Y, and Lesniak MS, Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro-Oncology, 2011.13(12): p. 1308-1323.
221. Jacobs JFM, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJM, Wesseling P, et al., Prognostic significance and mechanism ofTreg infiltration in human brain tumors. Journal of Neuroimmunology, 2010. 225(1-2): p. 195-199.
222. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, and Van Meir EG, Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer, 1994. 58(2): p. 240-7.
223. Vasco C, Canazza A, Rizzo A, Mossa A, Corsini E, Silvani A, et al., Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study. J Neurooncol, 2013.115(3): p. 353-63.
224. Zhou M, Bracci PM, McCoy LS, Hsuang G, Wiemels JL, Rice T, et al., Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time. International Journal of Cancer, 2015: p. n/a-n/a.
225. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G, Struyf S, et al., Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. European Journal of Immunology, 2001. 31(3): p. 812-22.
226. Kaminska B, Kocyk M, and Kijewska M, TGF beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol, 2013. 986: p. 171-87.
227. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, et al., Prostaglandin E2 Induces FOXP3 Gene Expression and TRegulatory Cell Function in Human CD4+ TCells. The Journal of Immunology, 2005.175(3): p. 1483-1490.
228. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, et al., COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells. Cancer Research, 2011. 71(7): p. 2664-2674.
229. Waight JD, Takai S, Marelli B, Qin G, Hance KW, Zhang D, et al., Cutting Edge: Epigenetic Regulation ofFoxp3 Defines a Stable Population ofCD4+ Regulatory T Cells in Tumors from Mice and Humans. J Immunol, 2015.194(3): p. 878-82.
230. Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, et al., Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory Tcells. Immunity, 2012. 36(2): p. 262-75.
231. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004.10(9): p. 942-9.
232. Gobert M, Treilleux I, Bendriss-Vermare N, BachelotT, Goddard-Leon S, Arfi V, etal., Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Research, 2009. 69(5): p. 2000-9.
233. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, et al., CD4+CD25high Tcells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 2006.177(10): p. 7398-405.
234. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al., CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory Tcells in gastric cancer. IntJ Cancer, 2008.122(10): p. 2286-93.
235. Maruyama T, Kono K, Izawa S, Mizukami Y, Kawaguchi Y, Mimura K, et al., CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis Esophagus, 2010. 23(5): p. 422-9.
236. Ishida T, Specific Recruitment of CC Chemokine Receptor 4-Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege. Cancer Research, 2006. 66(11): p. 5716-5722.
237. Li Y-Q, Liu F-F, ZhangX-M, Guo X-J, Ren M-J, and Fu L, Tumor Secretion ofCCL22 Activates Intratumoral Treg Infiltration and Is Independent Prognostic Predictor of Breast Cancer. PLoS One, 2013. 8(10): p. e76379.
238. Watanabe S, Watanabe R, Oton-Leite AF, Alencar Rde C, Oliveira JC, Leles CR, et al., Analysis of cell proliferation and pattern of invasion in oral squamous cell carcinoma. J Oral Sci, 2010. 52(3): p. 417-24.
239. Liu J, Zhang N, Li Q, Zhang W, Ke F, LengQ, etal., Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One, 2011. 6(4): p. e19495.
240. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, et al., Tumorinfiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol, 2012.189(12): p. 5602-11.
241. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, et al., Disruption ofCCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol, 2009.182(3): p. 1746-55.
242. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, et al., Tumor evasion of the immune system by converting CD4+CD25-Tcells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol, 2007.178(5): p. 2883-92.
243. Schreiber TH, Wolf D, Bodero M, and Podack E, Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. OncoImmunology, 2012.1(5): p. 642-648.
244. Setiady YY, Coccia JA, and Park PU, In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. European Journal of Immunology, 2010. 40(3): p. 780-6.
245. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, and Huang B, Selective depletion of CD4+CD25+Foxp3+ regulatory Tcells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Research, 2010. 70(12): p. 4850-8.
246. Curran MA, Montalvo W, Yagita H, and Allison JP, PD-1 and CTLA-4 combination blockade expands infiltrating Tcells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA, 2010.107(9): p. 4275-80.
247. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, et al., CD4(+)CD25(+) immunoregulatory Tcells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity, 2002.16(2): p. 311-23.
248. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, et al., Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One, 2010. 5(5): p. e10436.
249. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al., A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood, 2011.118(18): p. 4853-62.
250. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, et al., In silico identified CCR4 antagonists target regulatory Tcells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA, 2008.105(29): p. 10221-6.
251. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, etal., Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One, 2009. 4(11): p. e8084.
252. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al., Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol, 2009. 27(2): p. 186-92.
253. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, etal., Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Research, 2011. 71(4): p. 1263-71.
254. Glass R and Synowitz M, CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathologica, 2014.128(3): p. 347-62.
255. Lawson LJ, Perry VH, Dri P, and Gordon S, Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 1990. 39(1): p. 151-70.
256. Perry VH and Gordon S, Macrophages and the nervous system. IntRevCytol, 1991. 125: p. 203-44.
257. Saijo K and Glass CK, Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol, 2011.11(11): p. 775-87.
258. Morimura T, Neuchrist C, Kitz K, Budka H, Scheiner O, Kraft D, et al., Monocyte subpopulations in human gliomas: expression ofFc and complement receptors and correlation with tumor proliferation. Acta Neuropathologica, 1990. 80(3): p. 287-94.
259. Roggendorf W, Strupp S, and Paulus W, Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathologica, 1996. 92(3): p. 288-93.
260. Gordon S and Taylor PR, Monocyte and macrophage heterogeneity. Nat Rev Immunol, 2005. 5(12): p. 953-64.
261. Mantovani A, Sozzani S, Locati M, Allavena P, and Sica A, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 2002. 23(11): p. 549-55.
262. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, and Jaillon S, Tumor associated macrophages and neutrophils in cancer. Immunobiology, 2013. 218(11): p. 1402-1410.
263. Biswas SK, A distinct and unique transcriptional program expressed by tumorassociated macrophages (defective NF- B and enhanced IRF-3/STAT1 activation). Blood, 2006.107(5): p. 2112-2122.
264. Kennedy BC, Maier LM, D'Amico R, Mandigo CE, Fontana EJ, Waziri A, et al., Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunology, 2009.10: p. 11.
265. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al., Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science, 2010. 330(6005): p. 841-5.
266. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al., Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci, 2014.17(1): p. 131-43.
267. Gomez Perdiguero E, Schulz C, and Geissmann F, Development and homeostasis of "resident" myeloid cells: the case of the microglia. Glia, 2013. 61(1): p. 112-20.
268. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al., A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science, 2012. 336(6077): p. 86-90.
269. Goldmann T, Wieghofer P, Muller PF, WolfY, Varol D, Yona S, etal., A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci, 2013.16(11): p. 1618-26.
270. Carvalho da Fonseca AC and Badie B, Microglia and Macrophages in Malignant Gliomas: Recent Discoveries and Implications for Promising Therapies. Clinical and Developmental Immunology, 2013. 2013(4): p. 1-5.
271. Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, and Preston JK, Dexamethasoneinduced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. Journal of Neurosurgery, 2000. 93(4): p. 634-9.
272. Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, and Yong VW, A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin- 6 axis. Carcinogenesis, 2012. 33(2): p. 312-9.
273. Okada M, Saio M, Kito Y, Ohe N, Yano H, Yoshimura S, et al., Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but notMCP-1. Int J Oncol, 2009. 34(6): p. 1621-7.
274. Held-Feindt J, Hattermann K, Muerkoster SS, Wedderkopp H, Knerlich-Lukoschus Ungefroren H, et al., CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp Cell Res, 2010. 316(9): p. 1553-66.
275. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, and Brown JM, Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest, 2010.120(3): p. 694-705.
276. Badie B, Schartner J, Klaver J, and Vorpahl J, In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurgery, 1999. 44(5): p. 1077-82; discussion 1082-3.
277. Alterman RL and Stanley ER, Colony stimulating factor-1 expression in human glioma. Mol Chem Neuropathol, 1994. 21(2-3): p. 177-88.
278. Suzuki Y, Funakoshi H, Machide M, Matsumoto K, and Nakamura T, Regulation of cell migration and cytokine production by HGF-like protein (HLP)/macrophage stimulating protein (MSP) in primary microglia. Biomed Res, 2008. 29(2): p. 77-84.
279. Rao JS, Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer, 2003. 3(7): p. 489-501.
280. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al., Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med, 2012.18: p. 519-27.
281. Tsai JC, Goldman CK, and Gillespie GY, Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. Journal of Neurosurgery, 1995. 82(5): p. 864-73.
282. Magnus T, Schreiner B, Korn T, Jack C, Guo H, Antel J, et al., Microglial expression of the B7family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci, 2005. 25(10): p. 2537-46.
283. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al., Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine, 2002. 8(8): p. 793-800.
284. Badie B, Schartner J, Prabakaran S, Paul J, and Vorpahl J, Expression of Fas ligand by microglia: possible role in glioma immune evasion. Journal of Neuroimmunology, 2001.120(1-2): p. 19-24
285. Walker DG, Chuah T, Rist MJ, and Pender MP, T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. Journal of Neuroimmunology, 2006. 175(1-2): p. 59-68
286. Zhang L, Liu W, Alizadeh D, Zhao D, Farrukh O, Lin J, et al., S100B attenuates microglia activation in gliomas: possible role of STAT3 pathway. Glia, 2011. 59(3): 486-98.
287. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, and Badie B, Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia, 2009. 57(13): p. 1458-67.
288. Yu H, Pardoll D, and Jove R, STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 2009. 9(11): p. 798-809.
289. Fujiwara Y, Komohara Y, Ikeda T, and Takeya M, Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Science, 2011.102(1): p. 206-11.
290. Fujiwara Y, Komohara Y, Kudo R, Tsurushima K, Ohnishi K, Ikeda T, et al., Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation ofSTAT3. Oncology Reports, 2011. 26(6): p. 1533-7.
291. Zhu X, Fujita M, Snyder LA, and Okada H, Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol, 2011.104(1): p. 83-92.
292. da Fonseca AC and Badie B, Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin Dev Immunol, 2013. 2013: p. 264124.
293. Gabrilovich DI, Ostrand-Rosenberg S, and Bronte V, Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol, 2012.12(4): p. 253-68.
294. Serafini P, Borrello I, and Bronte V, Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology, 2006.16(1): p. 53-65.
295. Gabrilovich D, Mechanisms and functional significance of tumour-induced dendriticcell defects. Nat Rev Immunol, 2004 4(12): p. 941-52.
296. Gantt S, Gervassi A, Jaspan H, and Horton H, The role of myeloid-derived suppressor cells in immune ontogeny. Front Immunol, 2014. 5: p. 387.
297. Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, Kappler J, and Marrack P, Control ofBcl-2 expression by reactive oxygen species. Proc Natl Acad Sci USA, 2003. 100(25): p. 15035-40.
298. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al., Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Research, 2009. 69(4): p. 1553-60.
299. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, and Ochoa AC, Regulation ofT cell receptor CD3zeta chain expression by L-arginine. J Biol Chem, 2002. 277(24): p. 21123-9.
300. Schmielau J and Finn OJ, Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Research, 2001. 61(12): p. 4756-60.
301. Mirghorbani M, Van Gool S, and Rezaei N, Myeloid-derived suppressor cells in glioma. Expert Rev Neurother, 2013.13(12): p. 1395-406.
302. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology, 2011.13(6): p. 591-9.
303. Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Petersen-Baltussen HM, Ter Laan M, et al., Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients With Glioma But Predominance ofCD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue. J Neuropathol Exp Neurol, 2015. 74(5): p. 390-400.
304. Chae M, Peterson TE, Balgeman A, Chen S, Zhang L, Renner DN, et al., Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloidderived suppressor cells in a murine model. Neuro-Oncology, 2014.
305. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, et al., COX-2 blockade suppressesgliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Research, 2011. 71(7): p. 2664-74
306. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al., Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One, 2012. 7(12): p. e50946
307. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, et al., Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res, 2011. 167(2): p. e211-9.
308. Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V, et al., Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. OncoImmunology, 2013. 2(3): p. e23562.
309. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al., Tumor-associated macrophages and survival in classic Hodgkin 's lymphoma. N Engl J Med, 2010. 362(10): p. 875-85.
310. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, etal., Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology, 2010.12(4): p. 351-65.
311. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, etal., Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity, 2010. 32(6): p. 790-802.
312. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, and Berraondo P, Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol, 2011.186(2): p. 807-15.
313. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al., IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest, 2011.121(12): p. 4746-57.
314. Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, et al., Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther, 2014. 21(1): p. 38-44.
315. Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010. 363(8): p. 711-23.
316. Pardoll DM, The blockade of immune checkpoints in cancer immunotherapy. 2012: p. 1-13.
317. Keir ME, Butte MJ, Freeman GJ, and Sharpe AH, PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology, 2008. 26: p. 677-704.
318. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, and Zang X, Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med, 2015. 21(1): p. 24-33.
319. Carreno BM and Collins M, The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annual Review of Immunology, 2002. 20: p. 29-53.
320. Chen L, Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 2004.4(5): p. 336-47.
321. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA, 2004. 101(49): p. 17174-9.
322. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al., Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer, 2005.104(10): p. 2084-91.
323. Mu CY, Huang JA, Chen Y, Chen C, and ZhangXG, High expression ofPD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol, 2011. 28(3): p. 682-8.
324. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, and Nishimura M, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 2004.10(15): p. 5094-100.
325. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, et al., Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat, 2014.146(1): p. 15-24.
326. Wei B, Wang L, Zhao X, Du C, Guo Y, and Sun Z, The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. Tumour Biol, 2014 35(4): p. 2923-9.
327. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, et al., Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. European Journal of Immunology, 2003. 33(10): p. 2706-16.
328. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al., Endothelial expression ofPD-L1 and PD-L2 down-regulates CD8+ Tcell activation and cytolysis. European Journal of Immunology, 2003. 33(11): p. 3117-26.
329. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, et al., Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med, 2003.198(1): p. 71-8.
330. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al., Loss of tumor suppressor PTENfunction increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 2006.13(1): p. 84-88.
331. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M. Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. Radiation Oncology Biology, 2013. 86(2): p. 343-349.
332. Berghoff AS, Kiesel B, Widhalm G, Wohrer A, Dieckmann K, Filipits M, et al., Analysis ofPD1 and PD-L1 Expression in Glioblastoma. Neuro-Oncology, 2014.16(suppl 2): p. ii12.
333. Liu Y, Carlsson R, Ambjorn M, Hasan M, Badn W, Darabi A, et al., PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients. Journal of Neuroscience, 2013. 33(35): p. 14231-14245.
334. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al., PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One, 2013. 8(6): p. e65821.
335. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 2006. 8(3): p. 190-8.
336. Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, et al., PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene, 2009. 28(2): p. 306-12.
337. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al., Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEKdependentpathway. Blood, 2007.110(1): p. 296-304.
338. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al., Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA, 2008.105(52): p. 20852-7.
339. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, and Bronte V, Myeloidderived suppressor cell heterogeneity in human cancers. Annals of the New York Academy of Sciences, 2014.1319(1): p. 47-65.
340. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al., Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Research, 2013. 73(6): p. 1733-41.
341. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al., Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med, 2009. 206(6): p. 1327-37.
342. Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, et al., Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol, 2009.182(4): p. 2102-12.
343. Wang G, Zhang S, Wang F, Li G, Zhang L, and Luan X, Expression and biological function of programmed death ligands in human placenta mesenchymal stem cells. Cell Biol Int, 2013. 37(2): p. 137-48.
344. Ascierto PA, Simeone E, Sznol M, Fu YX, and Melero I, Clinical Experiences With Anti- CD137and Anti-PD1 Therapeutic Antibodies. YSONC, 2010. 37(5): p. 508-516.
345. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al., Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. Clinical Cancer Research, 2007.13(7): p. 2158-2167.
346. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, et al., Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic Tlymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA, 1999. 96(26): p. 15074-9.
347. Leach DR, Krummel MF, and Allison JP, Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996. 271(5256): p. 1734-6.
348. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA, 2003.100(14): p. 8372-7.
349. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion ofCD25(+) regulatory Tcells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med, 2001.194(6): p. 823-32.
350. Schaer DA, Murphy JT, and WolchokJD, Modulation of GITRfor cancer immunotherapy. Current Opinion in Immunology, 2012. 24(2): p. 217-224.
351. Han S, Feng S, Xu L, Shi W, WangX, Wang H, et al., Tim-3 on peripheral CD4(+) and CD8(+) Tcells is involved in the development of glioma. DNA Cell Biol, 2014. 33(4): 245-50.
352. Belcaid Z, Phallen JA, ZengJ, See AP, Mathios D, GottschalkC, et al., Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One, 2014 9(7): p. e101764
353. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, and Selvan SR, Interleukin 10 in the tumor micro environment: a target for anticancer immunotherapy. Immunologic Research, 2011. 51(2-3): p. 170-182.
354. Horst HA, Scheithauer BW, Kelly PJ, and Kovach JS, Distribution of transforming growth factor-beta 1 in human astrocytomas. Hum Pathol, 1992. 23(11): p. 1284-8.
355. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, et al., Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. IntJ Cancer, 1995. 62(4): p. 386-92.
356. Samuels V, Barrett JM, Bockman S, Pantazis CG, and Allen MB, Jr., Immunocyto chemical study oftransforming growth factor expression in benign and malignant gliomas. Am J Pathol, 1989.134(4): p. 894-902.
357. Lee C, Mysteries of TGF-β paradox in benign and malignant cells. 2014: p. 1-5.
358. Connolly EC, Freimuth J, and Akhurst RJ, Complexities of TGF-beta targeted cancer therapy. IntJ Biol Sci, 2012. 8(7): p. 964-78.
359. Zitvogel L and Kroemer G, Targeting PD-1/PD-L1 interactions for cancer immunotherapy. OncoImmunology, 2012.1(8): p. 1223-1225.